The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma
dc.contributor.author | Roh, Michael H. | en_US |
dc.contributor.author | Schmidt, Lindsay | en_US |
dc.contributor.author | Placido, Jeremiah | en_US |
dc.contributor.author | Farmen, Sara | en_US |
dc.contributor.author | Fields, Kristina L. | en_US |
dc.contributor.author | Courey, Anthony J. | en_US |
dc.contributor.author | Arenberg, Douglas A. | en_US |
dc.contributor.author | Knoepp, Stewart M. | en_US |
dc.date.accessioned | 2012-11-07T17:04:29Z | |
dc.date.available | 2014-01-07T14:51:07Z | en_US |
dc.date.issued | 2012-11 | en_US |
dc.identifier.citation | Roh, Michael H.; Schmidt, Lindsay; Placido, Jeremiah; Farmen, Sara; Fields, Kristina L.; Courey, Anthony J.; Arenberg, Douglas A.; Knoepp, Stewart M. (2012). "The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma." Diagnostic Cytopathology 40(11): 949-955. <http://hdl.handle.net/2027.42/94238> | en_US |
dc.identifier.issn | 8755-1039 | en_US |
dc.identifier.issn | 1097-0339 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/94238 | |
dc.description.abstract | The importance of subclassifying pulmonary nonsmall cell carcinoma (NSCLC) in cytologic material is becoming increasingly paramount. Occasionally, cell blocks traditionally used for ancillary studies are sparsely cellular or acellular. Hence, we investigated the diagnostic utility of immunocytochemistry for Napsin‐A, TTF‐1, and p63 on direct smears of NSCLC. Immunohistochemistry for Napsin‐A was initially tested on a tissue microarray (TMA) composed of pulmonary adenocarcinoma. Subsequently, in 25 cases, immunocytochemistry for Napsin‐A, TTF‐1, and p63 was performed on cytologic direct smears. Smears were prepared from tumor cells scraped from lung resection specimens (n = 10), endobronchial ultrasound‐guided transbronchial fine‐needle aspirates (n = 13), and pelleted cell material from pleural effusions (n = 2). Immunohistochemistry utilizing the TMA revealed Napsin‐A positivity in 73% of pulmonary ADCs. Next, immunocytochemistry on direct cytologic smears demonstrated a Napsin‐A(+)/TTF‐1(+) immunophenotype in 15 of 18 adenocarcinomas; p63 was completely negative (n = 12) or only focally positive (n = 3) in these 15 adenocarcinomas. The remaining three adenocarcinomas were negative for all three markers. All six squamous cell carcinomas were Napsin‐A(−)/TTF‐1(−) and diffusely p63(+). In conclusion, direct smears represent a feasible and robust source of cellular material for immunocytochemical studies to diagnose pulmonary ADC and SQC. Our method allows the cytologist to confirm on site that material for diagnostic immunocytochemistry is present thereby serving as a safeguard in instances where the cell block is of insufficient cellularity. Diagn. Cytopathol. 2012. © 2011 Wiley Periodicals, Inc. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Lung Cancer | en_US |
dc.subject.other | Napsin‐A | en_US |
dc.subject.other | TTF‐1 | en_US |
dc.subject.other | P63 | en_US |
dc.subject.other | Cytology | en_US |
dc.title | The application and diagnostic utility of immunocytochemistry on direct smears in the diagnosis of pulmonary adenocarcinoma and squamous cell carcinoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Pathology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109 | en_US |
dc.contributor.affiliationum | Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan | en_US |
dc.identifier.pmid | 21500373 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/94238/1/21680_ftp.pdf | |
dc.identifier.doi | 10.1002/dc.21680 | en_US |
dc.identifier.source | Diagnostic Cytopathology | en_US |
dc.identifier.citedreference | Yang M, Nonaka D. A study of immunohistochemical differential expression in pulmonary and mammary carcinomas. Mod Pathol 2010; 23: 654 – 661. | en_US |
dc.identifier.citedreference | Travis WD, World Health Organization, International Agency for Research on Cancer. International Association for the Study of Lung Cancer, International Academy of Pathology. 2004. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus, and Heart. Lyon: IARC Press; 344 p. | en_US |
dc.identifier.citedreference | Ladanyi M, Pao W. Lung adenocarcinoma: Guiding EGFR‐targeted therapy and beyond. Mod Pathol 2008; 21 ( Suppl 2 ): S16 – S22. | en_US |
dc.identifier.citedreference | Travis WD. Pathology of lung cancer. Clin Chest Med 2002; 23: 65 – 81. | en_US |
dc.identifier.citedreference | Besse B, Ropert S, Soria JC. Targeted therapies in lung cancer. Ann Oncol 2007; 18 ( Suppl 9 ): ix135 – ix142. | en_US |
dc.identifier.citedreference | Herbst RS. Toxicities of antiangiogenic therapy in non‐small‐cell lung cancer. Clin Lung Cancer 2006; 8 ( Suppl 1 ): S23 – S30. | en_US |
dc.identifier.citedreference | Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non‐small‐cell lung cancer. J Clin Oncol 2004; 22: 2184 – 2191. | en_US |
dc.identifier.citedreference | Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy‐naive patients with advanced‐stage non‐small‐cell lung cancer. J Clin Oncol 2008; 26: 3543 – 3551. | en_US |
dc.identifier.citedreference | Mukhopadhyay S, Katzenstein AL. Subclassification of non‐small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF‐1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011; 35: 15 – 25. | en_US |
dc.identifier.citedreference | Rekhtman N, Brandt SM, Sigel CS, et al. Suitability of thoracic cytology for new therapeutic paradigms in non‐small cell lung carcinoma: High accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing. J Thorac Oncol 2011; 6: 451 – 458. | en_US |
dc.identifier.citedreference | Lau SK, Luthringer DJ, Eisen RN. Thyroid transcription factor‐1: A review. Appl Immunohistochem Mol Morphol 2002; 10: 97 – 102. | en_US |
dc.identifier.citedreference | Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Laboratory Med 2008; 132: 384 – 396. | en_US |
dc.identifier.citedreference | Hirano T, Gong Y, Yoshida K, et al. Usefulness of TA02 (napsin A) to distinguish primary lung adenocarcinoma from metastatic lung adenocarcinoma. Lung Cancer 2003; 41: 155 – 162. | en_US |
dc.identifier.citedreference | Chuman Y, Bergman A, Ueno T, et al. Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. FEBS Lett 1999; 462: 129 – 134. | en_US |
dc.identifier.citedreference | Suzuki A, Shijubo N, Yamada G, et al. Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. Pathol Res Pract 2005; 201: 579 – 586. | en_US |
dc.identifier.citedreference | Dejmek A, Naucler P, Smedjeback A, et al. Napsin A (TA02) is a useful alternative to thyroid transcription factor‐1 (TTF‐1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. Diagn Cytopathol 2007; 35: 493 – 497. | en_US |
dc.identifier.citedreference | Stoll LM, Johnson MW, Gabrielson E, et al. The utility of napsin‐A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol 2010; 118: 441 – 449. | en_US |
dc.identifier.citedreference | Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010; 34: 1805 – 1811. | en_US |
dc.identifier.citedreference | Ou SH, Zell JA. Carcinoma NOS is a common histologic diagnosis and is increasing in proportion among non‐small cell lung cancer histologies. J Thorac Oncol 2009; 4: 1202 – 1211. | en_US |
dc.identifier.citedreference | Khayyata S, Yun S, Pasha T, et al. Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine‐needle aspiration specimens. Diagn Cytopathol 2009; 37: 178 – 183. | en_US |
dc.identifier.citedreference | Abendroth CS, Dabbs DJ. Immunocytochemical staining of unstained versus previously stained cytologic preparations. Acta Cytol 1995; 39: 379 – 386. | en_US |
dc.identifier.citedreference | Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor‐1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010; 41: 20 – 25. | en_US |
dc.identifier.citedreference | Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240 – 247. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.